Author

Micha Levi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Organism:mouse· 4 Approach:experimental assay· 3 Approach:statistical model· 1

Frequent Co-Authors

Alessia Tagliavini· 2 shared Anna M. UptoniD· 2 shared Cécile PascaliD· 2 shared Chiara RoversiiD· 2 shared Clara Aguilar-PéreziD· 2 shared David J. Hermann· 2 shared Debra Flood· 2 shared Denise FedericoiD· 2 shared

Activity by Year

2025-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

Alessia Tagliavini

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Contribution of the novel oxazolidinone TBD09 (MK-7762) to regimens with bedaquiline and pretomanid in a mouse model of tuberculosis

Deepak V. Almeida, Paul J. Converse, Courtney Schill, Jin I. Lee, Micha Levi, Alexander Berg, Mdluli Khisi, Eric L. Nuermberger

This study evaluates TBD09's contribution to BPa-based tuberculosis regimens in mice, showing comparable bactericidal and sterilizing activity to linezolid with reduced toxicity.

bioRxiv · Sep 24, 2026 · PreprintMicrobiology

Next Generation TB Drug Combinations from the Pan-TB Consortium: Combination Efficacy and Contributions of Individual Agents, Evaluated in a BALB/c Mouse TB Model

Sylvie Sordello, Alain Le Coupanec, Zoï Vahlas, Chiara Roversi, ROBERTO VISENTIN, Xavier Boulenc, Denise Federico, Simone Zannoni, Simone Modolo, Augusto Celon, Roberto Petterlini, Cécile Pascal, Fanny Deglave, Alessia Tagliavini, Marco Pergher, , Anna M. Upton

The paper evaluates next-generation TB drug combinations in a mouse model, showing some regimens cure 90% of mice in under 2 months with faster sterilizing efficacy than existing treatments.

bioRxiv · Jun 23, 2026 · PreprintPharmacology & Toxicology

Nonclinical pharmacokinetics and relative efficacy of the first 25 novel tuberculosis drug combinations from the PAN-TB consortium: Use of the BALB/c relapsing mouse model and combination pharmacokinetics within a modeling-based framework

Sylvie Sordello, Alessia Tagliavini, Xavier Boulenc, Laure Brock, Simone Zannoni, Chiara Roversi, ROBERTO VISENTIN, Darren Metcalf, Denise Federico, Simone Modolo, Giulia Calusi, Roberto Petterlini, Guillaume R. Golovkine, Cécile Pascal, Emilie Huc‐Claustre, , Anna M. Upton

The paper evaluates 25 tuberculosis drug combinations in a mouse model, finding 15 combinations with T90 <5 months and three top combinations curing 90% of mice in <3 months.

bioRxiv · May 7, 2026 · PreprintMicrobiology

stormTB: A web-based simulator of a murine minimal-PBPK model for anti-tuberculosis treatments.

Roberto Visintainer, Anna Fochesato, Daniele Boaretti, Stefano Giampiccolo, Shayne Watson, Micha Levi, Federico Reali, Luca Marchetti

stormTB provides a web-based mPBPK model for simulating anti-TB drug treatments in mice, enabling pharmacokinetic comparisons and supporting 11 drugs.

Frontiers in Pharmacology · Jan 8, 2025Peer-reviewedPharmacology & Toxicology